儿童免疫性血小板减少症的规范治疗与管理

张爱军; 刘芹芹; 浦婷

doi:10.12372/jcp.2022.21e1625

临床儿科杂志 >

2022 , Vol. 40 >Issue 2: 81 - 86

DOI: https://doi.org/10.12372/jcp.2022.21e1625

专家笔谈

儿童免疫性血小板减少症的规范治疗与管理

张爱军 ,
刘芹芹 ,
浦婷

展开

山东大学齐鲁医院儿科（山东济南 250012）

张爱军（1978—）,女,青年编委,山东大学齐鲁医院儿科副主任,主任医师,医学博士,免疫学博士后,硕士研究生导师ORCID：0000-0002-6117-4560,哈佛大学高级访问学者。兼任中华医学会儿科学分会青年委员,中华医学会儿科学分会血液学组青年委员,中华医学会儿科分会互联网+专业委员会青年委员,中国研究型医院学会儿科学专业委员会青年委员,山东省儿科分会青年委员会副主任委员,山东省抗癌协会小儿肿瘤分会常务委员,山东省免疫学会青年委员。主持国家自然科学基金1项,省部级课题5项,发表SCI论文20余篇。

收稿日期: 2021-11-22

网络出版日期: 2022-02-11

基金资助

山东省自然科学基金重点项目(ZR202010220039);山东省重点研发计划(2019GSF108060)

收起

Standardized treatment and management of immune thrombocytopenia in children

Aijun ZHANG ,
Qinqin LIU ,
Ting PU

Expand

Department of Pediatrics, Shangdong University Qilu Hospital, Jinan 250012, Shandong, China

Received date: 2021-11-22

Online published: 2022-02-11

Fold

摘要

免疫性血小板减少症（ITP）是儿童时期最为常见的出血性疾病,由多种自身免疫机制介导,以孤立性血小板减少为主要临床特点。儿童ITP通常急性起病,相当比例的患儿可追溯到前驱感染或接种疫苗史,均可使其免疫失耐受,从而导致ITP的发生。儿童ITP异质性较强,目前越来越多的患儿病情反复,一线治疗效果不佳,迁延不愈,导致慢性ITP增加,临床医师应根据每例患儿特点作出相应的个体化治疗,给予合理规范的疾病管理,综合评估治疗效果,减少治疗相关并发症,提高患儿生活质量。

关键词： 免疫性血小板减少症; 规范治疗; 儿童

本文引用格式

张爱军 , 刘芹芹 , 浦婷 . 儿童免疫性血小板减少症的规范治疗与管理[J]. 临床儿科杂志, 2022 , 40(2) : 81 -86 . DOI: 10.12372/jcp.2022.21e1625

Abstract

Immune thrombocytopenia (ITP) is the most common bleeding disorde characterized by isolated thrombocytopenia in children. It is mediated by a variety of autoimmune mechanisms. Children with ITP usually have acute onset. A considerable proportion of patients can be traced back to the history of precursor infection or vaccination, which can make them immune intolerant, resulting in the occurrence of ITP. There is strong heterogeneity of ITP in children. At present, more and more children tend to relapse. The first-line treatment is not effective, and the protracted treatment leads to chronic ITP. Clinicians should make corresponding individualized treatment and give reasonable management according to the characteristics of each child to reduce treatment-related complications and improve the quality of life of children.

Key words： immune thrombocytopenia; standardized treatment; child

参考文献

[1]	梅恒, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J]. 临床内科杂志, 2021, 38(6):431-432.
[2]	Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11):2386-2393.
[3]	Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity[J]. Blood, 2009, 113(26):6511-6521.
[4]	Cecinati V, Principi N, Brescia L, et al. Vaccine admini-stration and the development of immune thrombo-cytopenic purpura in children[J]. Hum Vaccin Immunother, 2013, 9(5):1158-1162.
[5]	Audia S, Mahévas M, Samson M, et al. Pathogenesis of immune thrombocytopenia[J]. Autoimmun Rev, 2017, 16(6):620-632.
[6]	Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells[J]. Proc Natl Acad Sci U S A, 2016, 113(12):3329-3334.
[7]	Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun, 2015, 6:7737.
[8]	Zhao HY, Ma YH, Li DQ, et al. Low-dose chidamide restores immune tolerance in ITP in mice and humans[J]. Blood, 2019, 133(7):730-742.
[9]	Ikuse T, Toda M, Kashiwagi K, et al. Efficacy of eradication therapy on platelet recovery in pediatric immune thrombocytopenic purpura-case series and a systematic review[J]. Microorganisms, 2020, 8(10):1457.
[10]	中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J]. 中华儿科杂志, 2021, 59(10):810-819.
[11]	Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011, 117(16):4190-4207.
[12]	侯明, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8):617-623.
[13]	Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune throm-bocytopenia: a prospective multicenter randomized trial[J]. Blood, 2016, 127(3):296-302.
[14]	Sadeghi A, Hosseini SF, Jouzdani SR. Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: a randomized clinical trial[J]. J Res Med Sci, 2020, 25:88.
[15]	Ma J, Fu L, Chen Z, et al. High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study[J]. Int J Hematol, 2020, 112(6):773-779.
[16]	Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial[J]. Am J Hematol, 2020, 95(12):1542-1552.
[17]	Wang J, Li Y, Wang C, et al. Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis[J]. Biomed Res Int, 2018: 1316096.
[18]	Feng Q, Xu M, Yu YY, et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia[J]. J Thromb Haemost, 2017, 15(9):1845-1858.
[19]	Grace RF, Shimano KA, Bhat R, et al. Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes[J]. Am J Hematol, 2019, 94(7):741-750.
[20]	Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP[J]. Blood, 2015, 125(10):1541-1547.
[21]	Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out[J]. Blood, 2018, 131(11):1172-1182.
[22]	Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP[J]. Br J Haematol, 2018, 181(2):183-195.
[23]	Álvarez-Román MT, Rivas Pollmar MI, Bernardino JI, et al. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia[J]. AIDS, 2016, 30(7):1141-1142.
[24]	Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody[J]. Platelets, 2015, 26(5):495-497.
[25]	Revilla N, Corral J, Miñano A, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content[J]. Platelets, 2019, 30(6):743-751.
[26]	Alioglu B, Tasar A, Ozen C, et al. An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report[J]. Pathophysiol Haemost Thromb, 2010, 37(2-4):55-58.
[27]	de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug[J]. Ann Hematol, 2005, 84(Suppl 1):3-8.
[28]	Han P, Hou Y, Zhao Y, et al. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia[J]. Blood, 2021, 138(8):674-688.
[29]	Zhou H, Qin P, Liu Q, et al. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia[J]. Am J Hematol, 2019, 94(12):1374-1381.
[30]	Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP?[J]. Hematol Am Soc Hematol Educ Program, 2018, 2018(1):405-411.
[31]	Khelif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study[J]. Am J Hematol, 2019, 94(2):200-208.
[32]	Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants[J]. Pediatr Blood Cancer, 2018, 65(1). doi: 10.1002/pbc.26736.
[33]	Heitink-Pollé KMJ, Nijsten J, Boonacker CWB, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis[J]. Blood, 2014, 124(22):3295-3307.
[34]	Schmidt DE, Wendtland Edslev P, Heitink-Pollé KMJ, et al. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia[J]. J Thromb Haemost, 2021, 19(1):121-130.
[35]	Adly AAM, Ragab IA, Ismail EAR, et al. Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia[J]. Platelets, 2015, 26(7):645-650.
[36]	王丽媛, 刘亢亢, 储金华, 等. 儿童免疫性血小板减少症病程慢性化影响因素的研究[J]. 中国实验血液学杂志, 2021, 29(3):881-886.
[37]	Levy-Mendelovich S, Aviner S, Sharon N, et al. Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course[J]. Pediatr Res, 2021, 90(1):93-98.
[38]	Gu H, Chen Z, Shi X, et al. Increased proportion of Th17/Treg cells at the new diagnosed stage of chronic immune thrombocytopenia in pediatrics: the pilot study from a multi-center[J]. Eur J Pediatr, 2021, 180(11):3411-3417.
[39]	Vrbensky JR, Nazy I, Toltl LJ, et al. Megakaryocyte apoptosis in immune thrombocytopenia[J]. Platelets, 2018, 29(7):729-732.
[40]	Iraqi M, Perdomo J, Yan F, et al. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro[J]. Haematologica, 2015, 100(5):623-632.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献